{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:28:46Z","timestamp":1791426526489,"version":"4.3.3"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ejps.2025.107210","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T15:05:36Z","timestamp":1752937536000},"page":"107210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Precipitation as key parameter for early oral drug absorption predictions, Part I: Acquisition of critical data"],"prefix":"10.1016","volume":"213","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2648-0187","authenticated-orcid":false,"given":"Sara","family":"Mayer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhizhou","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Weitschies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Krollik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejps.2025.107210_bib0001","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1177\/0091270003251122","article-title":"Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man","volume":"43","author":"Agrawal","year":"2003","journal-title":"J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.ejps.2025.107210_bib0002","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1016212804288","article-title":"A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability","volume":"12","author":"Amidon","year":"1995","journal-title":"Pharm. Res."},{"issue":"6","key":"10.1016\/j.ejps.2025.107210_bib0003","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1021\/js970372e","article-title":"P-glycoprotein (P-gp) mediated efflux in Caco-2 cell monolayers: the influence of culturing conditions and drug exposure on P-gp expression levels","volume":"87","author":"Anderle","year":"1998","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2025.107210_bib0004","unstructured":"AstraZeneca, 2012. Label: TENORMIN\u00ae (atenolol) tablets."},{"key":"10.1016\/j.ejps.2025.107210_bib0005","first-page":"77","article-title":"Principle of common-ion effect and its application in chemistry: a review","volume":"1","author":"Ayogu","year":"2020","journal-title":"J. Chem. Lett."},{"key":"10.1016\/j.ejps.2025.107210_bib0006","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1016\/j.xphs.2024.06.014","article-title":"A stratified analysis of supersaturation and precipitation effects based on the refined Developability Classification system (rDCS)","volume":"113","author":"Beran","year":"2024","journal-title":"J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.ejps.2025.107210_bib0007","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.ejpb.2014.08.011","article-title":"Prediction of oral absorption of cinnarizine\u2013a highly supersaturating poorly soluble weak base with borderline permeability","volume":"88","author":"Berlin","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"1","key":"10.1016\/j.ejps.2025.107210_bib0008","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ijpharm.2017.04.029","article-title":"Gastrointestinal behavior of itraconazole in humans - part 1: supersaturation from a solid dispersion and a cyclodextrin-based solution","volume":"525","author":"Brouwers","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2025.107210_bib0009","unstructured":"Bryant Ranch Prepack, 2010. Label: terazosin hydrochloride capsules."},{"key":"10.1016\/j.ejps.2025.107210_bib0010","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejpb.2018.12.010","article-title":"In vitro models for the prediction of in vivo performance of oral dosage forms: recent progress from partnership through the IMI OrBiTo collaboration","volume":"136","author":"Butler","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"12","key":"10.1016\/j.ejps.2025.107210_bib0011","doi-asserted-by":"crossref","first-page":"4940","DOI":"10.1002\/jps.22217","article-title":"The developability classification system: application of biopharmaceutics concepts to formulation development","volume":"99","author":"Butler","year":"2010","journal-title":"J. Pharm. Sci."},{"issue":"10","key":"10.1016\/j.ejps.2025.107210_bib0012","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1007\/s11095-010-0213-8","article-title":"Predicting intestinal precipitation- A case example for a basic BCS class II drug","volume":"27","author":"Carlert","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2025.107210_bib0013","unstructured":"Center for Drug Evaluation and Research (CDER), FDA, 2015. Clinical pharmacology and biopharmaceutics review(s): daklinza (Daclatasvir) (application number: 206843Orig1s000)."},{"key":"10.1016\/j.ejps.2025.107210_bib0014","series-title":"Annex 1: Summur of Product Characteristics - Erivedge","year":"2021"},{"issue":"8","key":"10.1016\/j.ejps.2025.107210_bib0015","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1021\/js9804011","article-title":"Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption","volume":"88","author":"Clark","year":"1999","journal-title":"J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.ejps.2025.107210_bib0016","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s13318-018-0532-4","article-title":"A physiologically based pharmacokinetic model for optimally profiling lamotrigine disposition and drug-drug interactions","volume":"44","author":"Conner","year":"2019","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.ejps.2025.107210_bib0017","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1124\/dmd.123.001429","article-title":"Recommendations on the use of multiple labels in Human mass balance studies","volume":"52","author":"Cuyckens","year":"2024","journal-title":"Drug Metab. Dispos."},{"issue":"6","key":"10.1016\/j.ejps.2025.107210_bib0018","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1021\/mp300140h","article-title":"The fraction dose absorbed, in humans, and high jejunal human permeability relationship","volume":"9","author":"Dahan","year":"2012","journal-title":"Mol. Pharm."},{"issue":"4","key":"10.1016\/j.ejps.2025.107210_bib0019","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1208\/s12248-009-9144-x","article-title":"Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs","volume":"11","author":"Dahan","year":"2009","journal-title":"AAPS J."},{"issue":"9","key":"10.1016\/j.ejps.2025.107210_bib0020","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1002\/jps.24258","article-title":"Direct in vivo Human intestinal permeability (Peff) determined with different clinical perfusion and intubation methods","volume":"104","author":"Dahlgren","year":"2015","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.ejps.2025.107210_bib0021","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00003088-198814010-00002","article-title":"Clinical pharmacokinetics of ketoconazole","volume":"14","author":"Daneshmend","year":"1988","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2025.107210_bib0022","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejpb.2019.07.005","article-title":"Rat intestinal drug permeability: a status report and summary of repeated determinations","volume":"142","author":"Dubbelboer","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"21","key":"10.1016\/j.ejps.2025.107210_bib0023","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1021\/jm000292e","article-title":"Prediction of drug absorption using multivariate statistics","volume":"43","author":"Egan","year":"2000","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejps.2025.107210_bib0024","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1124\/dmd.116.073585","article-title":"A physiologically-based pharmacokinetic modeling approach to predict drug-drug interactions of Sonidegib (LDE225) with perpetrators of CYP3A in cancer patients","volume":"45","author":"Einolf","year":"2017","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2025.107210_bib0025","unstructured":"European Medicines Agency, 2010. CHMP assessment report for Votrient, INN-pazopanib."},{"key":"10.1016\/j.ejps.2025.107210_bib0026","unstructured":"European Medicines Agency, 2015. Assessment report for Odomzo, INN-sonidegib."},{"issue":"1\u20132","key":"10.1016\/j.ejps.2025.107210_bib0028","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0378-5173(03)00372-7","article-title":"Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs","volume":"263","author":"Faassen","year":"2003","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2025.107210_bib0029","series-title":"Clinical Pharmacology and Biopharmaceutics Review(S)","year":"2008"},{"issue":"3","key":"10.1016\/j.ejps.2025.107210_bib0030","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/jphp.12875","article-title":"Development, current applications and future roles of biorelevant two-stage in vitro testing in drug development","volume":"70","author":"Fiolka","year":"2018","journal-title":"J. Pharm. Pharmacol."},{"issue":"8","key":"10.1016\/j.ejps.2025.107210_bib0031","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1016\/j.xphs.2020.04.023","article-title":"Biorelevant two-stage In vitro testing for rDCS classification and in PBPK modeling-case example Ritonavir","volume":"109","author":"Fiolka","year":"2020","journal-title":"J. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.ejps.2025.107210_bib0032","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.cmet.2014.09.018","article-title":"Metformin: from mechanisms of action to therapies","volume":"20","author":"Foretz","year":"2014","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.ejps.2025.107210_bib0033","article-title":"Lamotrigine: pharmacokinetics","volume":"12","author":"Garnett","year":"1997","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.ejps.2025.107210_bib0034","unstructured":"GlaxoSmithKline, 2009. Prescribing information: LAMICTAL\u00ae (lamotrigine)."},{"issue":"5","key":"10.1016\/j.ejps.2025.107210_bib0035","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1365-2125.2012.04281.x","article-title":"Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects","volume":"74","author":"Graham","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2025.107210_bib0036","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ejpb.2023.01.021","article-title":"Comparing the gastric emptying of 240 mL and 20 mL water by MRI and caffeine salivary tracer technique","volume":"184","author":"Grimm","year":"2023","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2025.107210_bib0037","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ejps.2018.01.039","article-title":"Evaluation and optimized selection of supersaturating drug delivery systems of posaconazole (BCS class 2b) in the gastrointestinal simulator (GIS): an in vitro-in silico-in vivo approach","volume":"115","author":"Hens","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2025.107210_bib0038","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejpb.2020.02.014","article-title":"Exploring the impact of real-life dosing conditions on intraluminal and systemic concentrations of atazanavir in parallel with gastric motility recording in healthy subjects","volume":"150","author":"Hens","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"12","key":"10.1016\/j.ejps.2025.107210_bib0039","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.1021\/acs.molpharmaceut.7b00396","article-title":"In Silico modeling approach for the evaluation of gastrointestinal dissolution, supersaturation, and precipitation of posaconazole","volume":"14","author":"Hens","year":"2017","journal-title":"Mol. Pharm."},{"issue":"3","key":"10.1016\/j.ejps.2025.107210_bib0040","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1021\/mp400465p","article-title":"In vitro-in vivo correlation of the effect of supersaturation on the intestinal absorption of BCS class 2 drugs","volume":"11","author":"Higashino","year":"2014","journal-title":"Mol. Pharm."},{"issue":"4","key":"10.1016\/j.ejps.2025.107210_bib0041","doi-asserted-by":"crossref","first-page":"157","DOI":"10.12793\/tcp.2016.24.4.157","article-title":"Absorption and half-life","volume":"24","author":"Holford","year":"2016","journal-title":"Transl. Clin. Pharmacol."},{"issue":"11","key":"10.1016\/j.ejps.2025.107210_bib0042","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.3390\/cancers12113322","article-title":"Epithelial transfer of the tyrosine kinase inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: implications for clinical resistance","volume":"12","author":"Honeywell","year":"2020","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.ejps.2025.107210_bib0043","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1128\/AAC.30.2.206","article-title":"Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers","volume":"30","author":"Huang","year":"1986","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9","key":"10.1016\/j.ejps.2025.107210_bib0044","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1038\/nprot.2007.303","article-title":"Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers","volume":"2","author":"Hubatsch","year":"2007","journal-title":"Nat. Protoc."},{"issue":"6","key":"10.1016\/j.ejps.2025.107210_bib0045","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1476-5381.2010.01127.x","article-title":"Principles of early drug discovery","volume":"162","author":"Hughes","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejps.2025.107210_bib0046","series-title":"Biopharmaceutics Classification System-Based Biowaiver (M9)","year":"2019"},{"key":"10.1016\/j.ejps.2025.107210_bib0047","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ijpharm.2019.05.028","article-title":"Application of an automated small-scale in vitro transfer model to predict in vivo precipitation inhibition","volume":"565","author":"Jede","year":"2019","journal-title":"Int. J. Pharm."},{"issue":"9","key":"10.1016\/j.ejps.2025.107210_bib0048","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1021\/acs.molpharmaceut.9b00534","article-title":"Improved prediction of in vivo supersaturation and precipitation of poorly soluble weakly basic drugs using a biorelevant bicarbonate buffer in a gastrointestinal transfer model","volume":"16","author":"Jede","year":"2019","journal-title":"Mol. Pharm."},{"issue":"63","key":"10.1016\/j.ejps.2025.107210_bib0049","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/psp.2013.41","article-title":"Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development","volume":"2","author":"Jones","year":"2013","journal-title":"CPT Pharmacometrics. Syst. Pharmacol."},{"key":"10.1016\/j.ejps.2025.107210_bib0050","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejpb.2016.03.020","article-title":"Prediction of the precipitation profiles of weak base drugs in the small intestine using a simplified transfer (\"dumping\") model coupled with in silico modeling and simulation approach","volume":"103","author":"Kambayashi","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"8","key":"10.1016\/j.ejps.2025.107210_bib0051","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1016\/j.xphs.2023.03.004","article-title":"Screening for differences in early exposure in the fasted State with in vitro methodologies can be challenging: experience with the BioGIT system","volume":"112","author":"Kostantini","year":"2023","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2025.107210_bib0052","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ejps.2013.09.008","article-title":"PBPK models for the prediction of in vivo performance of oral dosage forms","volume":"57","author":"Kostewicz","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.ejps.2025.107210_bib0053","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1211\/0022357022511","article-title":"Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine","volume":"56","author":"Kostewicz","year":"2004","journal-title":"J. Pharm. Pharmacol."},{"issue":"9","key":"10.1016\/j.ejps.2025.107210_bib0055","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1016\/j.xphs.2016.04.037","article-title":"Evaluation of the impact of excipients and an albendazole salt on albendazole concentrations in upper small intestine using an in vitro biorelevant gastrointestinal transfer (BioGIT) system","volume":"105","author":"Kourentas","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2025.107210_bib0056","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejps.2015.11.012","article-title":"An in vitro biorelevant gastrointestinal transfer (BioGIT) system for forecasting concentrations in the fasted upper small intestine: design, implementation, and evaluation","volume":"82","author":"Kourentas","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2025.107210_bib0057","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ejpb.2021.09.009","article-title":"The effect of buffer species on biorelevant dissolution and precipitation assays - comparison of phosphate and bicarbonate buffer","volume":"171","author":"Krollik","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"11","key":"10.1016\/j.ejps.2025.107210_bib0058","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15112523","article-title":"Caco-2 cell line standardization with pharmaceutical requirements and In vitro model suitability for permeability assays","volume":"15","author":"Kus","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2025.107210_bib0059","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejpb.2017.06.013","article-title":"Elucidation of the impact of cell culture conditions of Caco-2 cell monolayer on barrier integrity and intestinal permeability","volume":"119","author":"Lechanteur","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2025.107210_bib0060","series-title":"Handbook of Industrial Crystallization","first-page":"32","article-title":"Crystals and crystal growth","author":"Lee","year":"2019"},{"issue":"1","key":"10.1016\/j.ejps.2025.107210_bib0061","first-page":"1","article-title":"Increasing the robustness of biopharmaceutical precipitation assays - part I: derivative UV spectrophotometric method development for in-line measurements","volume":"111","author":"Lehmann","year":"2021","journal-title":"J. Pharm. Sci."},{"issue":"10\u201311","key":"10.1016\/j.ejps.2025.107210_bib0062","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1080\/00498250701704819","article-title":"Intestinal permeability and its relevance for absorption and elimination","volume":"37","author":"Lennern\u00e4s","year":"2007","journal-title":"Xenobiotica"},{"issue":"1","key":"10.1016\/j.ejps.2025.107210_bib0063","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/bdd.2510150102","article-title":"Dose-dependent pharmacokinetics: experimental observations and theoretical considerations","volume":"15","author":"Lin","year":"1994","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejps.2025.107210_bib0064","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106165","article-title":"Application of tiny-TIM as a mechanistic tool to investigate the in vitro performance of different itraconazole formulations under physiologically relevant conditions","volume":"173","author":"L\u00f3pez M\u00e1rmol","year":"2022","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2025.107210_bib0065","series-title":"Fast LC\/MS\/MS Analysis of Group 4 Pharmaceuticals from EPA-1694 With RRHD HILIC Plus","author":"Mack","year":"2011"},{"issue":"3","key":"10.1016\/j.ejps.2025.107210_bib0066","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/clpt.1982.42","article-title":"Dipyridamole kinetics","volume":"31","author":"Mahony","year":"1982","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.ejps.2025.107210_bib0067","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00280-016-3020-z","article-title":"A clinical drug-drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein\/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib","volume":"78","author":"Malhi","year":"2016","journal-title":"Cancer Chemother Pharmacol."},{"issue":"9","key":"10.1016\/j.ejps.2025.107210_bib0068","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics12090844","article-title":"Bottom-up physiologically based oral absorption modeling of free weak base drugs","volume":"12","author":"Matsumura","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2025.107210_bib100","article-title":"Precipitation as key parameter for early oral drug absorption predictions, Part II: Development of a predictive model","author":"Mayer","year":"2025","journal-title":"Eur. J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.ejps.2025.107210_bib0069","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.xphs.2021.01.011","article-title":"Biowaiver monographs for immediate release solid oral dosage forms: metformin hydrochloride","volume":"110","author":"Metry","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2025.107210_bib0070","series-title":"The Impact of Food Bioactives On Health. In vitro and Ex Vivo Models","first-page":"37","article-title":"The TNO gastro-intestinal model (TIM)","author":"Minekus","year":"2015"},{"issue":"3","key":"10.1016\/j.ejps.2025.107210_bib0071","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.xphs.2019.11.017","article-title":"Prediction of pH-dependent drug-drug interactions for basic drugs using physiologically based biopharmaceutics modeling: industry case studies","volume":"109","author":"Mitra","year":"2020","journal-title":"J. Pharm. Sci."},{"issue":"9","key":"10.1016\/j.ejps.2025.107210_bib0072","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1021\/mp500210c","article-title":"Quantification of gastrointestinal liquid volumes and distribution following a 240 mL dose of water in the fasted state","volume":"11","author":"Mudie","year":"2014","journal-title":"Mol. Pharm."},{"issue":"5","key":"10.1016\/j.ejps.2025.107210_bib0073","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1600-0773.1979.tb02350.x","article-title":"Pharmacokinetics of dipyridamole","volume":"44","author":"Nielsen-Kudsk","year":"1979","journal-title":"Acta Pharmacol. Toxicol. (Copenh)"},{"issue":"4","key":"10.1016\/j.ejps.2025.107210_bib0074","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/jphp.12951","article-title":"In vitro methods to assess drug precipitation in the fasted small intestine - a PEARRL review","volume":"71","author":"O'Dwyer","year":"2019","journal-title":"J. Pharm. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejps.2025.107210_bib0075","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejpb.2008.10.019","article-title":"Computer simulations using GastroPlus to justify a biowaiver for etoricoxib solid oral drug products","volume":"72","author":"Okumu","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"8","key":"10.1016\/j.ejps.2025.107210_bib0077","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1021\/acs.molpharmaceut.4c00526","article-title":"Parameterization of physiologically based biopharmaceutics models: workshop Summary report","volume":"21","author":"Pepin","year":"2024","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2025.107210_bib0078","article-title":"A combined in vitro in-silico approach to predict the oral bioavailability of borderline BCS class II\/IV weak base albendazole and its main metabolite albendazole sulfoxide","volume":"155","author":"Pettarin","year":"2020","journal-title":"Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci."},{"key":"10.1016\/j.ejps.2025.107210_bib0079","unstructured":"Promoting the Quality of Medicines (PQM), 2019. Product information report: albendazole chewable tablets. U.S. Pharmacopeial Convention."},{"issue":"12","key":"10.1016\/j.ejps.2025.107210_bib0080","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1007\/s11095-012-0844-z","article-title":"An in vitro methodology for forecasting luminal concentrations and precipitation of highly permeable lipophilic weak bases in the fasted upper small intestine","volume":"29","author":"Psachoulias","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2025.107210_bib0081","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejpb.2016.09.014","article-title":"Gastrointestinal dissolution, supersaturation and precipitation of the weak base indinavir in healthy volunteers","volume":"109","author":"Rubbens","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2025.107210_bib0082","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejps.2016.12.017","article-title":"Prediction of ketoconazole absorption using an updated in vitro transfer model coupled to physiologically based pharmacokinetic modelling","volume":"100","author":"Ruff","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"issue":"11","key":"10.1016\/j.ejps.2025.107210_bib0083","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1016\/j.xphs.2019.06.021","article-title":"Impact of acid-reducing agents on gastrointestinal physiology and design of biorelevant dissolution tests to reflect these changes","volume":"108","author":"Segregur","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2025.107210_bib0084","series-title":"An Evaluation of the Dissolution Behaviour of Poorly Soluble Acidic and Basic Drugs in Biorelevant Media (doctoral thesis)","author":"Shah","year":"2006"},{"issue":"4","key":"10.1016\/j.ejps.2025.107210_bib0085","first-page":"179","article-title":"The absolute oral bioavailability of selected drugs","volume":"27","author":"Sietsema","year":"1989","journal-title":"Int. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2025.107210_bib0086","series-title":"Biopharmaceutics Modeling and Simulations","first-page":"464","article-title":"Appendix A: general terminology","author":"Sugano","year":"2012"},{"issue":"9","key":"10.1016\/j.ejps.2025.107210_bib0087","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1002\/jps.24391","article-title":"Rate- and extent-limiting factors of oral drug absorption: theory and applications","volume":"104","author":"Sugano","year":"2015","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.ejps.2025.107210_bib0088","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejps.2005.02.017","article-title":"The use of an in vitro dissolution and absorption system to evaluate oral absorption of two weak bases in pH-independent controlled-release formulations","volume":"26","author":"Sugawara","year":"2005","journal-title":"Eur. J. Pharm. Sci."},{"issue":"10","key":"10.1016\/j.ejps.2025.107210_bib0089","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1023\/A:1020483911355","article-title":"Comparison of Human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs","volume":"19","author":"Sun","year":"2002","journal-title":"Pharm. Res."},{"issue":"6","key":"10.1016\/j.ejps.2025.107210_bib0090","first-page":"298","article-title":"The absolute and relative bioavailability of dipyridamole from different preparations and the in vitro-in vivo comparison","volume":"24","author":"Terhaag","year":"1986","journal-title":"Int. J. Clin. Pharmacol. Ther. Toxicol."},{"key":"10.1016\/j.ejps.2025.107210_bib0091","unstructured":"Teva Pharmaceuticals USA, 2016. Label: trimethoprim Tablets, USP 2158."},{"key":"10.1016\/j.ejps.2025.107210_bib0092","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120505","article-title":"Prediction of in vivo supersaturation and precipitation of poorly water-soluble drugs: achievements and aspirations","volume":"600","author":"Thakral","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2025.107210_bib0093","unstructured":"Therapeutic Goods Administration, 2019. Australian public assessment for Odomzo."},{"issue":"4","key":"10.1016\/j.ejps.2025.107210_bib0094","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1021\/acs.bioconjchem.7b00646","article-title":"Advances in polymer design for enhancing oral drug solubility and delivery","volume":"29","author":"Ting","year":"2018","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejps.2025.107210_bib0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2020.08.020","article-title":"The introduction of a new flexible in vivo predictive dissolution apparatus, GIS-alpha (GIS-\u03b1), to study dissolution profiles of BCS class IIb drugs, dipyridamole and ketoconazole","author":"Tsume","year":"2020","journal-title":"J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.ejps.2025.107210_bib0096","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0928-0987(95)00010-B","article-title":"Heterogeneity in the human intestinal cell line Caco-2 leads to differences in transepithelial transport","volume":"3","author":"Walter","year":"1995","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2025.107210_bib0097","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejps.2014.11.010","article-title":"Evaluation of fasted state human intestinal fluid as apical solvent system in the Caco-2 absorption model and comparison with FaSSIF","volume":"67","author":"Wuyts","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.ejps.2025.107210_bib0098","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1021\/ci010317y","article-title":"The \"latent membrane permeability\" concept: QSPR analysis of inter\/intralaboratory variable caco-2 permeability","volume":"42","author":"Yamashita","year":"2002","journal-title":"J. Chem. Inf. Comput. Sci."},{"issue":"4","key":"10.1016\/j.ejps.2025.107210_bib0099","doi-asserted-by":"crossref","first-page":"8","DOI":"10.14227\/DT140407P8","article-title":"Simplified biorelevant Media for screening dissolution performance of poorly soluble drugs","volume":"14","author":"Zoeller","year":"2007","journal-title":"Dissolution Technol."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092809872500209X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092809872500209X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T08:25:33Z","timestamp":1762331133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092809872500209X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":97,"alternative-id":["S092809872500209X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107210","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precipitation as key parameter for early oral drug absorption predictions, Part I: Acquisition of critical data","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107210","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107210"}}